Concepedia

Dosing Patterns and Economic Burden of Palbociclib Drug Wastage in HR+/HER2− Metastatic Breast Cancer

Anand A. Dalal, Patrick Gagnon‐Sanschagrin, Rebecca Burne, Annie Guérin, Geneviève Gauthier, Tania Small, Polly Niravath

Advances in Therapy · 2018 · 16 citations · 16 references

DOI

Concepts

References

16

Palbociclib and Letrozole in Advanced Breast Cancer

Richard S. Finn, Miguel Martín, Hope S. Rugo et al. · New England Journal of Medicine · 2016 · 2.9K citations

, , +17

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

Gabriel N. Hortobágyi, Salomon M. Stemmer, Howard A. Burris et al. · New England Journal of Medicine · 2016 · 2K citations · Full text

, , +17

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

Richard S. Finn, John Crown, István Láng et al. · The Lancet Oncology · 2014 · 1.9K citations

, , +17

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

Massimo Cristofanilli, Nicholas C. Turner, Igor Bondarenko et al. · The Lancet Oncology · 2016 · 1.8K citations

, , +17

Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

Nicholas C. Turner, Jungsil Ro, Fabrice André et al. · New England Journal of Medicine · 2015 · 1.6K citations · Full text

, , +10